Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and followed by three booster doses, according to the Expanded Programme on Immunisation.
The investigators hypothesise that a short course of TDF could greatly reduce the risk of HBV MTCT in pregnant women at high risk of MTCT (HBeAg positive or with high viral load).
This is a prospective, single-arm, open-label, descriptive, phase IV clinical trial in HBsAg and HBeAg positive pregnant women. Eligible pregnant women will receive 245 mg of tenofovir disoproxil fumarate once daily from 28 weeks of pregnancy until 6 weeks after delivery. Newborns will receive the hepatitis B vaccine, starting with one dose at birth, followed by three booster doses, in accordance with the expanded programme of vaccination.
The study aims to show that the addition of maternal antiviral treatment to vaccination at birth followed by three booster doses can be favourably considered in the context where vaccination alone is not sufficient to prevent transmission of the hepatitis B virus from mother to child. A total of 150 pregnant women will be included in the Tokombéré district.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| pregnant woman - tenofovir | Other | Participants will be started on tenofovir disoproxil fumarate (TDF) 245 mg one tablet per day from week 28 of pregnancy until 6 weeks postpartum. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fumarate, Tenofovir Disoproxil | Drug | all participants receive the intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of children with HBsAg positive at 9-12 months of life (W36 - W48) in the study population, | Proportion of HBsAg-positive children between 9 and 12 months of age in the study population, assessed by an automated test (mini VIDAS) | measured between 36 and 48 weeks of life of the child of the mothers included in the study |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of eligible women who accepted the intervention among eligible women offered the intervention (acceptance rate) | Proportion of women who took TDF continuously from the 7th month of pregnancy to 8 weeks postpartum (for at least 4 months) among women who accepted the intervention | measured from 7 months of pregnancy to 8 weeks postpartum |
Not provided
Inclusion criteria:
Exclusion criteria :
pregnant woman
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maaga DOURWE, MD | Contact | 0697073424 | dourwemaaga2@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Pierre ADOUKARA, MD | Hôpital de Tokombéré | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Privé de Tokombéré | Recruiting | Tokonbéré | Cameroon |
Not provided
| ID | Term |
|---|---|
| D000068698 | Tenofovir |
| ID | Term |
|---|---|
| D063065 | Organophosphonates |
| D009943 | Organophosphorus Compounds |
| D009930 | Organic Chemicals |
| D000225 | Adenine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Compliance with treatment | Compliance with treatment, estimated by self-report questionnaire and pill count | from 28 weeks of pregnancy to 8 weeks postpartum |
| Progression of viral load | Progression of viral load, HBsAg, HBeAg, HBcr and anti-HBe seroconversion in pregnant women during the treatment period (measured at inclusion and at the end of the TDF treatment) | measured from 24 weeks of pregnancy until the end of treatment |
| Estimate the protection rate of children with anti-HBs antibody level > 10 mIU/mL | Proportion of children with anti-HBs Ac > 10 mIU/ml at 9-12 months / total number of children in the study. | measured between 36 and 48 weeks of life of the child of the mothers included in the study |
| Assess the clinical and biological tolerance of TDF administration in mothers and children | Nature, number, frequency and intensity of adverse events in women; Nature, number, frequency, and intensity of adverse events in mothers and children and whether they are related to TDF use | measured from 28 weeks of pregnancy until the end of treatment |
| Assess the rate of women requiring extended treatment after delivery | Proportion of cytolytic or virological rebounds (with detectable viral load) after cessation of treatment estimated by measurement of ALT and HBV viral load at 12 weeks and 24 weeks postpartum when they previously had a non-detectable viral load at 8 weeks postpartum | Assess at 12 and 24 weeks postpartum |
| To assess the cost-effectiveness of the intervention (compared to vaccination alone, without hepatitis B immune globulin (Ig-anti HBV)) | Incremental cost-effectiveness ratio of the intervention compared to the situation where children receive vaccination only (HBV vaccination at birth + pentavalent) | To evaluate throughout the study |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |